Science Daily magazine said the new drug ximelagatran could eventually offer millions of people an alternative to the commonly prescribed anticoagulant warfarin.
Results of the UR study are reported in the Oct. 30 issue of the New England Journal of Medicine, which had a special section on scientific advances in the treatment of blood clots.
Lead author Dr. Charles Francis said ximelagatran was developed as an alternative to oral warfarin (Coumadin) in an effort to find a drug that's easier for patients and doctors to manage.
He said warfarin, a 50-year-old drug, requires constant laboratory monitoring, and has many side effects. Studies show ximelagatran is absorbed quickly, does not require adjustments or close monitoring, and has no food or drug interactions.
The new drug must yet be approved for use by the Food and Drug Administration.